Neurology 2001;56:312-316
© 2001 American Academy of Neurology
Articles
APOE genotype is a major predictor of long-term progression of disability in MS
J. Chapman, MD, PhD;,
S. Vinokurov, MSc;,
A. Achiron, MD, PhD;,
D. M. Karussis, MD, PhD;,
K. Mitosek–Szewczyk, MD;,
M. Birnbaum, PhD;,
D. M. Michaelson, PhD; and
A. D. Korczyn, MD, MSc
From the Departments of Neurology (Drs. Chapman, Achiron, and Korczyn), Physiology and Pharmacology (Drs. Chapman, Vinokurov, and Korczyn), and Biochemistry (Dr. Chapman), Sackler Faculty of Medicine; Department of Neurology and Neuroimmunology Clinic (Drs. Chapman, Birnbaum, and Korczyn), Tel Aviv Medical Center; Neuroimmunology Unit (Dr. Achiron), Sheba Medical Center; Department of Neurobiochemistry and Life Sciences (Dr. Michaelson), Tel Aviv University; Department of Neurology (Dr. Karussis), Hadassah Medical Center, Jerusalem, Israel; and Teaching Department of Neurology (Dr. Mitosek–Szewczyk), School of Medicine, Lublin, Poland.
Address correspondence and reprint requests to Dr. A.D. Korczyn, Sierazki Chair of Neurology, Tel Aviv University, Israel; e-mail: neuro13{at}ccsg.tau.ac.il
BACKGROUND AND OBJECTIVE: The authors recently reported that the APOE  4 allele is associated with significantly greater progression of disability in a 2-year follow-up of patients with MS. In this study, these findings are substantiated and extended in a much larger group of patients followed for up to 40 years.
METHODS: Two hundred five patients with clinically definite MS who were genotyped for the APOE 4 carrier state were included. Groups of patients with (n = 41) and without (n = 164) APOE 4 alleles were compared for latency to expanded disability status scale (EDSS) scores of 4.0 and 6.0 by Kaplan–Meier analysis with the log rank test. The results were adjusted for age at onset and sex by Cox regression analysis.
RESULTS: The APOE 4 allele frequency in patients with MS (0.10) was similar to that in the general Israeli population. There was a significant effect of APOE genotype on the latency to reach EDSS 4.0 and 6.0 (p = 0.0002 and p = 0.0006 by two-tailed log rank test). Median latencies were shorter by 12 and 11 years in the APOE 4 group for these outcomes. These results were significant after adjustment for age at onset and sex.
CONCLUSIONS: The APOE 4 allele is associated with significantly faster progression of disability in MS. This is the first genetic factor to be identified with a major impact on the progression of disability in this disease.
This article has been cited by other articles:
|
|
|
|
 
O. Gray, H Abdeen, G. McDonnell, C. Patterson, C. Graham, and S. Hawkins
An investigation of susceptibility loci in benign, aggressive and primary progressive multiple sclerosis in Northern Irish population
Multiple Sclerosis,
March 1, 2009;
15(3):
299 - 303.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Koutsis, M. Panas, E. Giogkaraki, C. Potagas, G. Karadima, C. Sfagos, and D. Vassilopoulos
APOE {varepsilon}4 is associated with impaired verbal learning in patients with MS
Neurology,
February 20, 2007;
68(8):
546 - 549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B A Parmenter, D R Denney, S G Lynch, L S Middleton, and L M Harlan
Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms
Multiple Sclerosis,
January 1, 2007;
13(1):
25 - 32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. A. Wishart, A. J. Saykin, L. A. Rabin, R. B. Santulli, L. A. Flashman, S. J. Guerin, A. C. Mamourian, D. R. Belloni, C. H. Rhodes, and T. W. McAllister
Increased Brain Activation During Working Memory in Cognitively Intact Adults With the APOE {epsilon}4 Allele
Am J Psychiatry,
September 1, 2006;
163(9):
1603 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-Q. Li, G. D. Sempowski, S. E. McKenna, D. T. Laskowitz, C. A. Colton, and M. P. Vitek
Apolipoprotein E-Derived Peptides Ameliorate Clinical Disability and Inflammatory Infiltrates into the Spinal Cord in a Murine Model of Multiple Sclerosis
J. Pharmacol. Exp. Ther.,
September 1, 2006;
318(3):
956 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al.
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers
Neurology,
May 9, 2006;
66(9):
1373 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Mahley, K. H. Weisgraber, and Y. Huang
Inaugural Article: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease
PNAS,
April 11, 2006;
103(15):
5644 - 5651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M J Sedano, P Calmarza, L Perez, and J M Trejo
No association of apolipoprotein E {epsilon}4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis
Multiple Sclerosis,
February 1, 2006;
12(1):
13 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Pinholt, J L Frederiksen, P S Andersen, and M Christiansen
Apo E in multiple sclerosis and optic neuritis: the Apo E-o4 allele is associated with progression of multiple sclerosis
Multiple Sclerosis,
October 1, 2005;
11(5):
511 - 515.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, et al.
Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
Arch Neurol,
September 1, 2005;
62(9):
1345 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cocco, A. Sotgiu, G. Costa, M. R. Murru, C. Mancosu, R. Murru, M. Lai, P. Contu, and M. G. Marrosu
HLA-DR,DQ and APOE genotypes and gender influence in Sardinian primary progressive MS
Neurology,
February 8, 2005;
64(3):
564 - 566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Wilczak, G S. Ramsaransing, J Mostert, D Chesik, and J De Keyser
Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis
Multiple Sclerosis,
February 1, 2005;
11(1):
13 - 15.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. E. Wahrle, H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J. D. Fryer, T. Kowalewski, and D. M. Holtzman
ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE
J. Biol. Chem.,
September 24, 2004;
279(39):
40987 - 40993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Zakrzewska-Pniewska, M Styczynska, A Podlecka, R Samocka, B Peplonska, M Barcikowska, and H Kwiecinski
Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(3):
266 - 271.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J N. Zwemmer, T van Veen, L van Winsen, G J van Kamp, F Barkhof, C H Polman, and B M. Uitdehaag
No major association of A poE genotype with disease characteristics and MRI findings in multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(3):
272 - 277.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(1_suppl):
S23 - S30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis,
May 1, 2004;
10(3_suppl):
S23 - S30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Santos, M. do Carmo Costa, M. E. Rio, M. J. Sa, M. Monteiro, A. Valenca, A. Sa, J. Dinis, J. Figueiredo, L. B. de Almeida, et al.
Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin
Multiple Sclerosis,
April 1, 2004;
10(2):
153 - 157.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. De Stefano, M. L. Bartolozzi, B. Nacmias, V. Zipoli, M. Mortilla, L. Guidi, G. Siracusa, S. Sorbi, A. Federico, and M. P. Amato
Influence of Apolipoprotein E {epsilon}4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis
Arch Neurol,
April 1, 2004;
61(4):
536 - 540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Mazurek
Reduced N-acetylaspartate Levels and Cognitive Decline
Arch Neurol,
February 1, 2004;
61(2):
296 - 296.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. van Veen, L. van Winsen, J. B.A. Crusius, N. F. Kalkers, F. Barkhof, A. S. Pena, C. H. Polman, and B. M.J. Uitdehaag
{alpha}B-Crystallin genotype has impact on the multiple sclerosis phenotype
Neurology,
November 11, 2003;
61(9):
1245 - 1249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Karussis, D M Michaelson, N Grigoriadis, A D Korezyn, R Mizrachi-Koll, S Chapman, O Abramsky, and J Chapman
Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis
Multiple Sclerosis,
October 1, 2003;
9(5):
476 - 480.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Niino, S Kikuchi, T Fukazawa, I Yabe, and K Tashiro
Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis
Multiple Sclerosis,
August 1, 2003;
9(4):
382 - 386.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Diaz-Arrastia, Y. Gong, S. Fair, K. D. Scott, M. C. Garcia, M. C. Carlile, M. A. Agostini, and P. C. Van Ness
Increased Risk of Late Posttraumatic Seizures Associated With Inheritance of APOE{epsilon}4 Allele
Arch Neurol,
June 1, 2003;
60(6):
818 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Haddock, W. S. C. Poston, and J. E. Taylor
Neurocognitive Sequelae Following Coronary Artery Bypass Graft: A Research Agenda for Behavioral Scientists
Behav Modif,
January 1, 2003;
27(1):
68 - 82.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Enzinger, S. Ropele, S. Strasser-Fuchs, P. Kapeller, H. Schmidt, B. Poltrum, R. Schmidt, H.-P. Hartung, and F. Fazekas
Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E {epsilon}4 Allele
Arch Neurol,
January 1, 2003;
60(1):
65 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Schreiber, A B Oturai, L P Ryder, H O Madsen, O S Jorgensen, A Svejgaard, and P S Sorensen
Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E)
Multiple Sclerosis,
August 1, 2002;
8(4):
295 - 298.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Buljevac, H. Z. Flach, W. C. J. Hop, D. Hijdra, J. D. Laman, H. F. J. Savelkoul, F. G. A. van der Meche, P. A. van Doorn, and R. Q. Hintzen
Prospective study on the relationship between infections and multiple sclerosis exacerbations
Brain,
May 1, 2002;
125(5):
952 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Arnold and P.M. Matthews
MRI in the diagnosis and management of multiple sclerosis
Neurology,
April 23, 2002;
58(90084):
S23 - 31.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W Bruck, C Lucchinetti, and H Lassmann
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis,
April 1, 2002;
8(2):
93 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T Masterman, Z Zhang, D Hellgren, H Salter, M Anvret, L Lilius, L Lannfelt, and J Hillert
APOE genotypes and disease severity in multiple sclerosis
Multiple Sclerosis,
April 1, 2002;
8(2):
98 - 103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. A. DeSousa, R. H. Albert, and B. Kalman
Cognitive impairments in multiple sclerosis: A review
American Journal of Alzheimer's Disease and Other Dementias,
January 1, 2002;
17(1):
23 - 29.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. G. Becker, J. Chapman, A. D. Korczyn, and D. M. Michaelson
APOE genotype is a major predictor of long-term progression of disability in MS
Neurology,
December 1, 2001;
57(11):
2148 - 2149.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Fazekas, S. Strasser-Fuchs, H. Kollegger, T. Berger, W. Kristoferitsch, H. Schmidt, C. Enzinger, M. Schiefermeier, C. Schwarz, B. Kornek, et al.
Apolipoprotein E {epsilon}4 is associated with rapid progression of multiple sclerosis
Neurology,
September 11, 2001;
57(5):
853 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Lenz, L. Lu, S. B. Conant, N. A. Wolf, H. C. Gerard, J. A. Whittum-Hudson, A. P. Hudson, and R. H. Swanborg
A Chlamydia pneumoniae-Specific Peptide Induces Experimental Autoimmune Encephalomyelitis in Rats
J. Immunol.,
August 1, 2001;
167(3):
1803 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
